The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The ...
Amneal Pharmaceuticals has received FDA approval for Brekiya®, the first and only dihydroergotamine (DHE) autoinjector designed for patients to self-administer for acute migraine and cluster headaches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results